Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Diclofenac · Cataflam, Diclofenac Potassium

Small molecule · Inhibitor of cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2) · developed by Novartis

Approved FDA, Nov 1993
1 Registered trials

What is Diclofenac?

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), blocking prostaglandin synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cataflam, Diclofenac Potassium, Zipsor, ZORVOLEX
Drug type
Small molecule
Targets
cyclooxygenase-1 (PTGS1), cyclooxygenase-2 (PTGS2)
Mechanism
Inhibitor of cyclooxygenase-1 (PTGS1) and cyclooxygenase-2 (PTGS2)
Pathways
prostaglandin synthesis, arachidonic acid metabolism
Therapy area
Musculoskeletal
Developer
Novartis
In trials of
TEVA
FDA status
Approved as Cataflam, Diclofenac Potassium, Zipsor (November 24, 1993), NDA020142 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 3, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03949673 Phase 2 Osteoarthritis, Knee Terminated TEVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteoarthritis, HipOsteoarthritis, Knee

Other drugs acting on PTGS1 / PTGS2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.